Reported revenues of $5.7 million in 4Q23, up 77% over prior year
Full year revenues of $18.5 million, up 49% over prior year
Gross Margin of 90% in 4Q23 and 86% for full year
CMS.
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery.
TriSalus Life Sciences, Inc. (TLSI), Thursday announced the real-world safety and clinical outcomes data, published in Current Medical Research and Opinion, for TriNav device for the treatment of patients with hepatocellular carcinoma or HCC and liver metastases.
TriSalus Life Sciences, Inc. (TLSI), Thursday announced the real-world safety and clinical outcomes data, published in Current Medical Research and Opinion, for TriNav device for the treatment of patients with hepatocellular carcinoma or HCC and liver metastases.